Document is current
Any future updates will be listed below
-
Authors
Wuyts, Wim A
Dahlqvist, Caroline
Slabbynck, Hans
Schlesser, Marc
Gusbin, Natacha
Compere, Christophe
Maddens, Sofie
Kirchgaessler, Klaus-Uwe
Bartley, Karen
Bondue, Benjamin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01366209 at ClinicalTrials.govnct00287716 at ClinicalTrials.govDocuments that mention this clinical trial
M27 Effect of pirfenidone on breathlessness as measured by the ucsd-sobq score in patients with idiopathic pulmonary fibrosis (ipf) with moderate lung function impairment
https://doi.org/10.1136/thoraxjnl-2017-210983.449
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
https://doi.org/10.1007/s12325-023-02565-3
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis
https://doi.org/10.1136/thoraxjnl-2021-218577
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
https://doi.org/10.1136/thoraxjnl-2017-210983.454
The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial
https://doi.org/10.1007/s41030-024-00267-x
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
https://doi.org/10.1136/bmjresp-2018-000323
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
https://doi.org/10.1136/bmjresp-2015-000105
nct00287729 at ClinicalTrials.govDocuments that mention this clinical trial
M27 Effect of pirfenidone on breathlessness as measured by the ucsd-sobq score in patients with idiopathic pulmonary fibrosis (ipf) with moderate lung function impairment
https://doi.org/10.1136/thoraxjnl-2017-210983.449
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis
https://doi.org/10.1136/thoraxjnl-2021-218577
M28 Deferring treatment with pirfenidone results in loss of lung function that is not recovered by later treatment initiation
https://doi.org/10.1136/thoraxjnl-2017-210983.450
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
https://doi.org/10.1136/thoraxjnl-2017-210983.454
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
https://doi.org/10.1016/s0140-6736(11)60405-4
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
https://doi.org/10.1136/bmjresp-2018-000323
nct01335464 at ClinicalTrials.govDocuments that mention this clinical trial
M27 Effect of pirfenidone on breathlessness as measured by the ucsd-sobq score in patients with idiopathic pulmonary fibrosis (ipf) with moderate lung function impairment
https://doi.org/10.1136/thoraxjnl-2017-210983.449
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis
https://doi.org/10.1136/thoraxjnl-2021-218577
M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity
https://doi.org/10.1136/thoraxjnl-2017-210983.454
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
https://doi.org/10.1016/s0140-6736(11)60405-4
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
https://doi.org/10.1136/bmjresp-2018-000323
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
https://doi.org/10.1136/bmjresp-2015-000105
nct01335477 at ClinicalTrials.govDocuments that mention this clinical trial
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
https://doi.org/10.1007/s40273-016-0480-2
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
https://doi.org/10.1136/bmjresp-2018-000397
Documents that mention this clinical trial
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
https://doi.org/10.1136/bmjresp-2018-000331
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
https://doi.org/10.1007/s40273-016-0480-2
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
https://doi.org/10.1136/bmjresp-2018-000397
-
Funding
Funding for this research was provided by:
Genentech, Inc. and F. Hoffmann-La Roche, Ltd.
